Single Psilocybin Dose Boosts Smokers' Odds of Quitting by Over 6 Times

New Johns Hopkins study finds psychedelic compound far outperforms nicotine patches for smoking cessation

Mar. 19, 2026 at 7:00am

Got story updates? Submit your updates here. ›

A new clinical trial from Johns Hopkins University found that participants who took a single dose of psilocybin, the active compound in magic mushrooms, had more than six times greater odds of being cigarette-free at the six-month mark compared to those using nicotine patches. The study enrolled 82 current smokers, with one group receiving psilocybin in a guided session and the other using nicotine patches, both alongside 13 weeks of cognitive behavioral therapy. At six months, 17 people in the psilocybin group had stayed off cigarettes, while only four in the nicotine patch group had done the same.

Why it matters

Smoking remains the leading cause of preventable death in the United States, yet current quit-smoking medications and therapies have long-term success rates of only 20-30%. This study suggests psilocybin could offer a novel and significantly more effective approach to smoking cessation, potentially helping millions of Americans kick the habit.

The details

The study participants in the psilocybin group lay in a room wearing eye shades and listening to soft music, with facilitators present to keep them comfortable. The psilocybin experience itself was described as 'self-directed.' Researchers noted that psilocybin appears to trigger a genuine shift in perspective and a new sense of agency, rather than just mimicking or replacing nicotine like existing medications. The intensive therapeutic structure around the psilocybin session also seemed central to the outcome.

  • The study enrolled 82 current smokers in March 2026.
  • Participants received either psilocybin or nicotine patches over 13 weeks of cognitive behavioral therapy.
  • At the 6-month mark, the results were assessed.

The players

Matthew Johnson

The study's lead author and a professor of psychiatry at Johns Hopkins University.

Brian Barnett

An addiction psychiatrist at the Cleveland Clinic Lerner College of Medicine who was not involved in the study.

Megan Piper

The director of the UW Center for Tobacco Research and Intervention.

Got photos? Submit your photos here. ›

What they’re saying

“I was surprised by the sheer magnitude of the effect.”

— Matthew Johnson

“It's a very different treatment approach from just trying to replace or sort of mimic the drug that's being misused.”

— Brian Barnett, addiction psychiatrist

“It's not the drug by itself here. It's really harnessing the neuroplastic and learning effects that happen after the exposure.”

— Brian Barnett, addiction psychiatrist

What’s next

The National Institutes of Health has already funded a larger ongoing trial that includes a placebo arm, which will help replicate the findings and draw firmer conclusions about psilocybin's efficacy for smoking cessation.

The takeaway

This study suggests psilocybin could offer a groundbreaking new approach to helping smokers quit, with success rates far exceeding existing medications and therapies. If the results hold in larger trials, psilocybin could become a powerful tool in the fight against the leading cause of preventable death in the US.